Systemic Inflammatory Indicators as Prognosticators in Glioblastoma Patients: A Comprehensive Meta-Analysis

Yang, Chia-Han; Wen, Hongbin; Zhao, Yuhang; Huang, Wen-Hong; Wang, Xinghuan; Li, Zhiqiang

doi:10.3389/fneur.2020.580101

Cited by 27 publications

(41 citation statements)

References 59 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that peripheral blood inflammatory markers are associated with the prognosis of small cell lung cancer, 28 bladder cancer, 29 hepatocellular carcinoma, 30 gastrointestinal cancers, 31 and other forms of malignancy. 32–34 Our present study also demonstrated that NLR, PLR, and LMR, were all significantly associated with rNACT. In addition, we found that a reduction in platelet count was associated with an increased risk of non-rNACT in patients with LACC.…”

Section: Discussionsupporting

confidence: 81%

Development and Validation of a Nomogram for the Estimation of Response to Platinum-Based Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer

Chen¹,

Wang²,

Zeng³

et al. 2021

CMAR

View full text Add to dashboard Cite

Purpose: Non-response to platinum-based neoadjuvant chemotherapy (non-rNACT) reduces the surgical outcomes of patients with locally advanced cervical cancer (LACC). The development of an accurate preoperative method to predict a patient's response to NACT (rNACT) could help surgeons to manage therapeutic intervention in a more appropriate manner. Patients and Methods: We recruited a total of 341 consecutive patients who underwent platinum-based NACT followed by radical surgery (RS) at the Hubei Cancer Hospital between January 1, 2010 and April 1, 2020. All patients had been diagnosed with stage Ib2-IIa2 cervical cancer in accordance with the 2009 International Federation of Gynecology and Obstetrics (FIGO) classification system. First, we created a training cohort of patients who underwent NACT+RS (n=239) to develop a nomogram. We then validated the performance of the nomogram in a validation cohort of patients who underwent NACT+RS (n=102). Data analysis was conducted from October 1, 2020. First, we determined overall survival (OS) and progression-free survival (PFS) after NACT+RS. Multivariate logistic regression was then used to identify independent risk factors that were associated with the response to rNACT; these were then incorporated into the nomogram. Results: The analysis identified several significant differences between the rNACT and non-rNACT groups, including neutrophil-lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), lymphocyte monocyte ratio (LMR), platelet count, and FIGO stage. The performance of the rNACT nomogram score exhibited a robust C-index of 0.76 (95% confidence interval [CI]: 0.65 to 0.87) in the training cohort and high C-index of 0.71 (95% CI: 0.62 to 0.78) in the validation cohort. Clinical impact curves showed that the nomogram had good predictive ability. Conclusion: We successfully established an accurate and optimized nomogram that could be used preoperatively to predict rNACT in patients with LACC. This model can be used to evaluate the risk of an individual patient experiencing rNACT and therefore facilitate the choice of treatment.

show abstract

Section: Discussionsupporting

confidence: 81%

Development and Validation of a Nomogram for the Estimation of Response to Platinum-Based Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer

Chen¹,

Wang²,

Zeng³

et al. 2021

CMAR

View full text Add to dashboard Cite

show abstract

“…NLR has been reported to be of prognostic value for various cancers, including GB [ 8 , 9 ]. Our findings are consistent with those of several studies showing an association, in univariate analysis, of higher preoperative NLR values (cutoffs ranging from 1.7–7) with poor OS in GB patients.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, molecular markers, such as isocitrate dehydrogenase (IDH) mutations and O 6 -methylguanine-DNA-methyltransferase (MGMT) hypermethylation are increasingly being used as predictors of prognosis and therapeutic response in GB patients [ 5 , 6 , 7 ]. There is growing evidence to suggest that preoperative hematological biomarkers, which reflect the tumor microenvironment to some extent, could be used as diagnostic and prognostic markers in several cancers, including GB [ 8 , 9 ]. For example, previous studies have indicated that neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) are associated with the clinical outcomes of GB [ 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…There is growing evidence to suggest that preoperative hematological biomarkers, which reflect the tumor microenvironment to some extent, could be used as diagnostic and prognostic markers in several cancers, including GB [ 8 , 9 ]. For example, previous studies have indicated that neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) are associated with the clinical outcomes of GB [ 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide

Clavreul

Lemée

Soulard

et al. 2021

Cancers

View full text Add to dashboard Cite

Purpose: The survival times of glioblastoma (GB) patients after the standard therapy including safe maximal resection followed by radiotherapy plus concomitant and adjuvant temozolomide are heterogeneous. In order to define a simple, reliable method for predicting whether patients with isocitrate dehydrogenase (IDH)-wildtype GB treated with the standard therapy will be short- or long-term survivors, we analyzed the correlation of preoperative blood counts and their combined forms with progression-free survival (PFS) and overall survival (OS) in these patients. Methods: Eighty-five patients with primary IDH-wildtype GB treated with the standard therapy between 2012 and 2019 were analyzed retrospectively. Cox proportional hazards models and Kaplan–Meier analysis were used to investigate the survival function of preoperative hematological parameters. Results: Preoperative high neutrophil-to-lymphocyte ratio (NLR, >2.42), high platelet count (>236 × 109/L), and low red blood cell (RBC) count (≤4.59 × 1012/L) were independent prognostic factors for poorer OS (p = 0.030, p = 0.030, and p = 0.004, respectively). Moreover, a high NLR was an independent prognostic factor for shorter PFS (p = 0.010). We also found that, like NLR, preoperative high derived NLR (dNLR, >1.89) was of poor prognostic value for both PFS (p = 0.002) and OS (p = 0.033). A significant correlation was observed between NLR and dNLR (r = 0.88, p < 0.001), which had a similar prognostic power for OS (NLR: AUC = 0.58; 95% CI: [0.48; 0.68]; dNLR: AUC = 0.62; 95% CI: [0.51; 0.72]). Two scores, one based on preoperative platelet and RBC counts plus NLR and the other on preoperative platelet and RBC counts plus dNLR, were found to be independent prognostic factors for PFS (p = 0.006 and p = 0.002, respectively) and OS (p < 0.001 for both scores). Conclusion: Cheap, routinely ordered, preoperative assessments of blood markers, such as NLR, dNLR, RBC, and platelet counts, can predict the survival outcomes of patients with IDH-wildtype GB treated with the standard therapy.

show abstract

“…It appears that cancer cells and neutrophils work in a two-way mechanism; neutrophil-secreted cytokines help the tumor to progress while tumor cells secret chemotactic factor that can increase neutrophil count. In addition, Yang et al reported the association of elevated platelet count with worse overall survival of glioblastoma patients [ 46 ].…”

Section: Inflammationmentioning

confidence: 99%

Dynamic Intercell Communication between Glioblastoma and Microenvironment through Extracellular Vesicles

et al. 2022

View full text Add to dashboard Cite

Glioblastoma is simultaneously the most common and most aggressive primary brain tumor in the central nervous system, with poor patient survival and scarce treatment options. Most primary glioblastomas reoccur and evolve radio- and chemoresistant properties which make them resistant to further treatments. Based on gene mutations and expression profiles, glioblastoma is relatively well classified; however, research shows that there is more to glioblastoma biology than that defined solely by its genetic component. Specifically, the overall malignancy of the tumor is also influenced by the dynamic communication to its immediate and distant environment, as important messengers to neighboring cells in the tumor microenvironment extracellular vesicles (EVs) have been identified. EVs and their cargo can modulate the immune microenvironment and other physiological processes, and can interact with the host immune system. They are involved in tumor cell survival and metabolism, tumor initiation, progression, and therapy resistance. However, on the other hand EVs are thought to become an effective treatment alternative, since they can cross the blood–brain barrier, are able of specific cell-targeting and can be loaded with various therapeutic molecules.

show abstract

Systemic Inflammatory Indicators as Prognosticators in Glioblastoma Patients: A Comprehensive Meta-Analysis

Cited by 27 publications

References 59 publications

Development and Validation of a Nomogram for the Estimation of Response to Platinum-Based Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer

Development and Validation of a Nomogram for the Estimation of Response to Platinum-Based Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer

A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide

Dynamic Intercell Communication between Glioblastoma and Microenvironment through Extracellular Vesicles

Contact Info

Product

Resources

About